Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
961-980 of 1,743 trials

Atezolizumab for Muscle-Invasive Bladder Cancer

We are studying whether atezolizumab can help patients with muscle-invasive bladder cancer who cannot have surgery after chemo-radiotherapy. The trial looks at how well it works and its impact on patients' quality of life.

Muscle-Invasive Bladder Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology

Genetically Modified T-Cells for ROR1 Positive Tumors

We are assessing the safety and tolerability of a new treatment using genetically modified T-cells for patients with ROR1 positive tumors. This study aims to understand how these cells may help in treating this type of cancer.

Mantle Cell LymphomaOvarian CancerAdrenocortical Carcinoma>2 yearsSafety phase (I)Oncology

Heart Procedure: Protamine Use in Aortic Valve Replacement

We are studying whether protamine can help reduce major bleeding and ischemic events in patients after transcatheter aortic valve replacement. This trial also examines other safety factors and complications related to the procedure.

Transcatheter Aortic Valve Replacement (TAVR)>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Prostate Cancer: Re-treatment with [177Lu]Lu-PSMA

We are studying the effects of re-treating men with metastatic castration-resistant prostate cancer using [177Lu]Lu-PSMA. This trial aims to see if this treatment can help improve survival and quality of life.

Metastatic Prostate Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncologyUrology

Head and Neck Cancer: Cetuximab with Chemotherapy

We are studying a combination of cetuximab and chemotherapy followed by immunotherapy for patients with recurrent or metastatic head and neck cancer. The goal is to see if this treatment improves survival and response rates for those with a specific PD-L1 score.

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Advanced Solid Tumors: DS-2243a Treatment

We are testing a new drug called DS-2243a in people with advanced solid tumors. This study aims to see how safe it is and how well it works compared to existing treatments.

Advanced Solid Tumor>2 yearsSafety phase (I)Oncology

Apixaban in Short Bowel Syndrome Patients

We are studying how the blood levels of apixaban differ in patients with short bowel syndrome who require long-term IV nutrition. This research may help improve treatment strategies for these patients.

Short Bowel Syndrome>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInternal Medicine

Early Triple-Negative Breast Cancer: Durvalumab Study

We are investigating the effects of Durvalumab in patients with early-stage triple-negative breast cancer before surgery. This study aims to see if it can improve treatment outcomes.

Triple Negative Breast Cancer>2 yearsEfficacy phase (II)Oncology

B-cell Non-Hodgkin Lymphoma: Loncastuximab Tesirine Study

We are testing a new treatment combining Loncastuximab Tesirine with other anti-cancer agents for patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma. The goal is to evaluate its safety and potential effectiveness.

B-cell Non-Hodgkin's Lymphoma>2 yearsSafety phase (I)Oncology

Colchicine for Peripheral Artery Disease

We are studying whether a low dose of colchicine can help reduce serious heart and limb problems in patients with peripheral artery disease. This research aims to improve safety and outcomes for those affected.

Peripheral Arterial Disease>2 yearsConfirmation phase (III)Investigational MedicinesCardiology

Brain Surgery Pain Management: Nerve Block Comparison

We are comparing two types of nerve blocks to see which one helps reduce pain and improve recovery for patients undergoing brain surgery. This study aims to find the best option for managing discomfort during the procedure.

Patients Undergoing Craniotomy for Supratentorial Mass>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineNeurologyOtolaryngology

Colorectal Cancer: Encorafenib and Cetuximab with Pembrolizumab

We are studying a combination of medications for patients with BRAF V600E-mutant metastatic colorectal cancer. The goal is to see if this combination works better than pembrolizumab alone.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Prostate Cancer: Darolutamide Addition Study

We are studying whether adding darolutamide to standard treatment helps men with metastatic castration-resistant prostate cancer live longer without cancer progression.

Metastatic Castration-Resistant Prostate Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyUrology

Multiple Myeloma: Etentamig and Iberdomide Study

We are investigating the safety and effects of a new treatment combining etentamig and iberdomide for patients with relapsed or refractory multiple myeloma. This study aims to find the best doses and assess how well the treatment works.

Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Breast Cancer: New Eye Safety Drug Study

We are investigating the safety of a new drug for breast cancer patients, specifically looking at its effects on eye health. This study aims to ensure that the treatment does not harm vision.

Breast Cancer>2 yearsSafety phase (I)OncologyOphthalmology

Solid Cancers: NILK-2401 Antibody Study

We are testing a new antibody treatment for solid cancers, both alone and with another cancer therapy. This study aims to find out how effective it may be for patients.

Advanced Solid Tumor>2 yearsSafety phase (I)Oncology

Bladder Cancer: Nadofaragene Firadenovec Treatment

We are studying the safety and effectiveness of nadofaragene firadenovec, given alone or with chemotherapy or immunotherapy, for adults with non-muscle invasive bladder cancer that hasn't responded to BCG therapy.

High-risk Non-Muscle-Invasive Bladder Cancer>2 yearsConfirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyUrology

Fluid Overload in ICU: Furosemide Treatment

We are studying whether a diuretic called furosemide helps critically ill patients with fluid overload recover better than a placebo. The focus is on increasing the number of days alive and out of the hospital after 90 days.

Fluid Overload>2 yearsMonitoring phase (IV)Standard MedicinesPartially RemoteCardiologyInternal MedicinePulmonology

Distal Radius Fracture: Brachial Plexus Nerve Block

We are studying whether an ultrasound-guided nerve block helps adults with distal radius fractures manage pain better than standard treatment during closed reduction. This trial will assess both the benefits and potential risks.

Distal Radius Fracture>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineNeurologyOrthopedics and Traumatology

Colorectal Polypectomy: Anticoagulation Study

We are investigating whether continuing blood-thinning medication during polypectomy is safe for patients. The goal is to see if it helps reduce the risk of blood clots during the procedure.

Patients on Anticoagulants for Colonoscopy>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteGastroenterologyHematology